Vanguard Group
GBT

Vanguard Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Vanguard Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,282,173
Closed -$428M – 4626
2022
Q3 		$428M Buy
6,282,173
+262,742
+4% +$14.5M 0.01% 920
2022
Q2 		$192M Sell
6,019,431
-4,831
-0.1% -$141K 0.01% 1443
2022
Q1 		$209M Buy
6,024,262
+31,120
+0.5% +$930K ﹤0.01% 1529
2021
Q4 		$175M Buy
5,993,142
+178,743
+3% +$5.54M ﹤0.01% 1688
2021
Q3 		$148M Sell
5,814,399
-48,220
-0.8% -$1.42M ﹤0.01% 1770
2021
Q2 		$205M Buy
5,862,619
+285,864
+5% +$11.2M 0.01% 1620
2021
Q1 		$227M Buy
5,576,755
+116,273
+2% +$5.34M 0.01% 1519
2020
Q4 		$236M Buy
5,460,482
+132,907
+2% +$6.55M 0.01% 1369
2020
Q3 		$294M Sell
5,327,575
-192,011
-3% -$12.2M 0.01% 1028
2020
Q2 		$348M Sell
5,519,586
-8,609
-0.2% -$590K 0.01% 936
2020
Q1 		$282M Buy
5,528,195
+56,733
+1% +$3.8M 0.01% 934
2019
Q4 		$435M Sell
5,471,462
-138,128
-2% -$8.19M 0.01% 897
2019
Q3 		$272M Buy
5,609,590
+243,464
+5% +$12.7M 0.01% 1145
2019
Q2 		$282M Buy
5,366,126
+485,866
+10% +$27.9M 0.01% 1142
2019
Q1 		$258M Buy
4,880,260
+275,458
+6% +$13.5M 0.01% 1178
2018
Q4 		$189M Buy
4,604,802
+402,359
+10% +$15.1M 0.01% 1278
2018
Q3 		$160M Buy
4,202,443
+108,137
+3% +$4.79M 0.01% 1540
2018
Q2 		$185M Buy
4,094,306
+231,569
+6% +$10.5M 0.01% 1399
2018
Q1 		$187M Buy
3,862,737
+586,252
+18% +$32.7M 0.01% 1329
2017
Q4 		$129M Buy
3,276,485
+65,708
+2% +$2.45M 0.01% 1588
2017
Q3 		$99.7M Buy
3,210,777
+277,526
+9% +$7.8M ﹤0.01% 1715
2017
Q2 		$80.2M Buy
2,933,251
+397,271
+16% +$11.8M ﹤0.01% 1788
2017
Q1 		$93.5M Buy
2,535,980
+726,366
+40% +$18.3M ﹤0.01% 1684
2016
Q4 		$26.1M Buy
1,809,614
+335,414
+23% +$5.89M ﹤0.01% 2298
2016
Q3 		$34M Buy
1,474,200
+195,736
+15% +$3.73M ﹤0.01% 2112
2016
Q2 		$21.2M Buy
1,278,464
+443,440
+53% +$8.95M ﹤0.01% 2306
2016
Q1 		$13.2M Buy
835,024
+331,365
+66% +$5.89M ﹤0.01% 2466
2015
Q4 		$16.3M Buy
503,659
+454,940
+934% +$19.7M ﹤0.01% 2394
2015
Q3 		$2.05M Buy
+48,719
New +$2.3M ﹤0.01% 3367

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's GBT Position: Q4 2022 in Review

Vanguard Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 6,282,173 shares — an estimated $428M sold.

Vanguard Group first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $435M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Vanguard Group reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 6,282,173 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $428M.
  • Vanguard Group first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
  • Vanguard Group's Global Blood Therapeutics, Inc. position peaked at $435M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.